美年健康(002044.SZ):前三季度歸母淨利預增148.94%–166.96%
格隆匯10月17日丨美年健康(002044.SZ)公佈2023年前三季度業績預吿,2023年1月1日至2023年9月30日實現營業收入71.1億元–73億元,比上年同期增長22.95%–26.24%;歸屬於上市公司股東的淨利潤1.9億元–2.6億元,比上年同期增長148.94%–166.96%;扣除非經常性損益後的淨利潤1.9億元–2.6億元,比上年同期增長144.85%–161.37%;基本每股收益0.05元/股–0.07元/股。
2023年7月1日至2023年9月30日實現營業收入27.05億元–28.95億元,比上年同期下降4.88%–比上年同期增長1.80%;歸屬於上市公司股東的淨利潤1.8億元–2.5億元,比上年同期下降10.19%–35.30%;扣除非經常性損益後的淨利潤1.87億元–2.57億元,比上年同期下降5.17%–30.99%;基本每股收益0.05元/股–0.07元/股。
2023年前三季度營業收入較上年同期有22.95%–26.24%的增長,前三季度歸屬於上市公司股東的淨利潤較上年同期有148.94%–166.96%的增長。主要受益於整體經營環境進入需求推動、量價齊升的良性發展通道,公司持續發力高品質產品與優質專業服務以滿足客户需求,客流量與消費客單價呈現穩步上升趨勢。在上半年體檢行業傳統淡季,公司歷史性實現扭虧為盈;進入下半年體檢行業旺季,公司經營穩健有序,持續構建以品質驅動的運營體系。在數字化與信息化賦能下,不斷夯實醫療品質內功建設,持續推動重點學科建設,並通過精細化運營不斷升級醫質服務,進一步帶動客户滿意度、復購率與客單價的提升。公司三季度收入同比基本持平,主要系去年上半年受到外部環境影響,導致去年三季度營業收入基數較高。今年三季度由於門店規模增加,且在人力與系統等方面投入增加,導致成本與費用有所增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.